# A First in Human Study to Assess the Safety, Tolerability and Immunogenicity of a Single Dose of a Trivalent Inactivated Poliovirus Vaccine Based on Sabin Strains (sIPV) Given Intramuscularly in Healthy Adults

> **NCT03032588** · PHASE1 · COMPLETED · sponsor: **Janssen Vaccines & Prevention B.V.** · enrollment: 32 (actual)

## Conditions studied

- Healthy

## Interventions

- **BIOLOGICAL:** sIPV
- **BIOLOGICAL:** cIPV

## Key facts

- **NCT ID:** NCT03032588
- **Lead sponsor:** Janssen Vaccines & Prevention B.V.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-10-09
- **Primary completion:** 2018-05-18
- **Final completion:** 2018-05-18
- **Target enrollment:** 32 (ACTUAL)
- **Last updated:** 2025-02-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03032588

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03032588, "A First in Human Study to Assess the Safety, Tolerability and Immunogenicity of a Single Dose of a Trivalent Inactivated Poliovirus Vaccine Based on Sabin Strains (sIPV) Given Intramuscularly in Healthy Adults". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT03032588. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*